Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Jianxin Rong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China. Hauptthemen laut MEDLINE: Paclitaxel, Prodrugs, Iridium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Government Guide the Development of Local Science and Technology Special Funds.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Stimuli‐cleavable prodrug technology offers a promising strategy to mitigate the severe systemic toxicity associated with conventional chemotherapy. However, its clinical translation is hindered by insufficient and nonspecific activation within heterogeneous tumors. To address this challenge, an ultrasound (US)‐activated nanoplatform (PDTC@Ir/PTX 2 ‐TK NPs) that couples a binuclear iridium sonosensitizer (Ir‐DPP‐Ir) with a reactive oxygen species (ROS)‐responsive paclitaxel prodrug (PTX 2 ‐TK), encapsulated in a self‐crosslinked polycarbonate (PDTC) carrier, is constructed. The PDTC carrier, which contains 1,2‐dithiolane, promotes stability and prevents premature drug leakage. Ir‐DPP‐Ir functions as a potent sonosensitizer, generating multiple ROS (e.g., •OH, 1 O 2 , O 2 −· ) under therapeutic ultrasound. The PTX 2 ‐TK prodrug maintains pharmacologically inert in normal tissues but is highly sensitive to ROS, thereby avoiding off‐target effects and ensuring tumor‐specific activation. Upon US irradiation, over 99% of PTX 2 ‐TK is effectively activated, addressing the critical bottleneck of tumor‐specific prodrug activation. This synergistic sonodynamic‐chemotherapy strategy achieves potent tumor eradication (95.8% inhibition) and stimulates a robust anti‐tumor immune response, while significantly minimizing systemic toxicity associated with conventional PTX administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China.
- Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
ORCID-Profile: Haihua Xiao
Förderung
- Natural Science Foundation of Hebei Province
- Government Guide the Development of Local Science and Technology Special Funds
Zitieren
APA
Rong, J., Wu, X., Tang, D., Lv, F., Zhang, Q., Xiao, H., & Hu, X. (2026). Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503875
Vancouver
Rong J, Wu X, Tang D, Lv F, Zhang Q, Xiao H, et al. Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503875
BibTeX
@article{Rong2026,
author = {Rong, Jianxin and Wu, Xiaoya and Tang, Dongsheng and Lv, Furou and Zhang, Qingxin and Xiao, Haihua and Hu, Xiuli},
title = {Ultrasound‐Triggered Dinuclear Iridium Sonosensitizer Activates Paclitaxel Prodrug for Synergistic Sonodynamic‐Chemotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503875}
}
EUVIMED